Company news
Cardiff Oncology, Inc. (NASDAQ:CRDF) news
Cardiff Oncology, Inc. news releases on 6ix. Latest, Sep 14, 2026: Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement
Press releases & updates
Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement
September 14, 2026
Cardiff Oncology to Participate in September 2026 Conferences
September 2, 2026
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update
August 11, 2026
Cardiff Oncology Announces $10 Million Registered Direct Offering
July 15, 2026
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting
June 2, 2026
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference
June 1, 2026
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
May 21, 2026
Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update
May 14, 2026
Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity
April 27, 2026
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting
April 17, 2026
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth
April 8, 2026
Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer
March 20, 2026
Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting
March 18, 2026
Cardiff Oncology to Participate in Three Upcoming Investor Conferences
February 26, 2026
Cardiff Oncology to Participate in Three Upcoming Investor Conferences
February 25, 2026
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update
February 24, 2026
Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 18, 2026
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC
January 27, 2026
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
January 27, 2026
Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025
December 8, 2025
Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference
December 8, 2025
Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference
November 24, 2025
Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update
November 6, 2025
Cardiff Oncology to Participate in Two Upcoming Investor Conferences
November 4, 2025
Cardiff Oncology to Participate in Three Upcoming Investor Conferences
August 28, 2025
Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)
July 29, 2025
Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update
July 29, 2025
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC
June 17, 2025
Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025
June 2, 2025
Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update
May 8, 2025
Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients
April 23, 2025
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 15, 2025
Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer
April 15, 2025
Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
February 27, 2025
Cardiff Oncology to Present at Upcoming Investor Conferences
February 24, 2025
Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update
February 20, 2025
Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering
December 9, 2024
Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial
December 9, 2024
Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC
November 18, 2024
Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update
November 6, 2024
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
October 29, 2024
Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update
August 7, 2024
Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update
July 31, 2024
Cardiff Oncology to Present at the Jefferies Healthcare Conference
May 28, 2024
Cardiff Oncology to Present at Upcoming Investor Conferences in May
May 12, 2024
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
May 1, 2024
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
April 24, 2024
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
April 7, 2024
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
March 5, 2024
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
February 28, 2024